Drug-induced lupus is a side effect of deliberate ingestion of various medications, but its etiology, underlying mechanisms, and pathogenesis are puzzling. In vivo metabolic transformation of lupusinducing drugs to reactive products explains how a heterogeneous set of drugs can mediate the same disease syndrome. Evidence has accumulated that drugs are transformed by extracellular oxidation from reactive oxygen species and myeloperoxidase produced when neutrophils are activated, maximizing the in situ accumulation of reactive drug metabolites within lymphoid compartments. The metabolite of procainamide, procainamide hydroxylamine, displays diverse biologic properties, but no apparent autoimmune effect has been observed. However, when procainamide hydroxylamine was introduced into the thymus of young adult normal mice, a delayed but robust autoimmune response developed. Disruption of central T-cell tolerance by intrathymic procainamide hydroxylamine resulted in the production of chromatin-reactive T cells that apparently drove the autoantibody response in the periphery. Drug-induced autoantibodies in this mouse model were remarkably similar to those in patients with procainamide-induced lupus. Therefore, this system has considerable promise to provide insight into the initiating events in drug-induced lupus and may provide a paradigm for how other xenobiotics might induce systemic autoimmunity. Key words: autoantibodies, drug-induced, lupus, T cells, reactive drug metabolites, thymus. -Environ Health Perspect 1 07(suppl 5): 803-806 (1999). http.//ehpnetl.niehs.nih.gov/docs/l 999/suppl-5/803-806rubin/abstract.html
It has been known since the initial description almost five decades ago of a side effect of longterm medication with hydralazine (1,2) that certain drugs have a propensity for inducing autoantibodies and occasionally lupuslike symptoms. Over the years some 46 drugs have been implicated with various degrees of risk in the induction of lupuslike disease, 38 ofwhich are currently in use. Although drug-induced lupus is not a major clinical problem because it can be fully cured by discontinuing use of the medication, it is remarkable that a low molecular weight xenobiotic has capacity to initiate or sustain a well-defined systemic autoimmune disease. Not only might this phenomenon shed light on the process of self-/non-self-discrimination that normally operates to avoid autoimmunity, but it may offer a paradigm on how other xenobiotics disrupt the immune system. Drug-induced lupus occurs in approximately 20% of patients treated with the antiarrhythmic drug procainamide for 1-2 years, and almost all procainamide-treated patients eventually develop particular autoantibodies, whether or not lupuslike symptoms appear. From drugs such as procainamide, hydralazine, and quinidine, which have a rather high propensity of autoimmune manifestations in response to exposure, drug-induced lupus has become the best-documented example of an environmentally induced autoimmune disease due to a noninfectious agent.
The symptomology of drug-induced lupus and its objective features such as autoantibodies to chromatin-derived antigens are remarkably similar to those of systemic lupus erythematosus, a disease that arises spontaneously. Drug (5, 6) . PAHA can be detected after the perfusion of rat liver with procainamide in a blood-free environment (7). Hydralazine and isoniazid are also susceptible to hepatic oxidative metabolism (8, 9) . PAHA is taken up by erythrocytes, and oxyhemoglobin enhances its biologic activity (7, 10) , presumably by converting PAHA to nitrosoprocainamide (11, 12) . Together with the demonstration that rats treated with procainamide had increased liver lipid peroxide levels and antioxidant activity (13) drug-induced lupus; b) liver-generated xenobiotic metabolites typically bind to microsomes or macromolecules near their site of formation and fail to be produced in sufficient amounts to interact with in situ lymphocytes or antigen-presenting cells or to exit the liver in reactive forms; c) although drug metabolites might bind to self-antigen in the liver, lupusinducing drugs are very small and diverse in chemical structure, with little common structural information to specifically interact with the chromatin-derived targets that characterize the autoimmune response in drug-induced lupus (see "Role of T Cells in Drug-Induced Lupus"). Therefore, if in vivo metabolism is a prerequisite for initiating drug-induced lupus, an extrahepatic process may be involved in which reactive metabolites are generated within an immune compartment where they can act on the cellular elements of the immune system to prevent or break tolerance.
Using procainamide as the prototype, we were the first to report that activated peripheral blood neutrophils have capacity to metabolize procainamide to PAHA (14) ; the role of the respiratory burst and degranulation events associated with neutrophil activation was confirmed (15) and analyzed in detail (16) . Drug metabolism by neutrophils occurs in the extracellular environment, in which released myloperoxidase, acting with hydrogen peroxide produced upon neutrophil activation, enzymatically oxidizes copresent drugs (17) . All major pharmacologic classes of lupusinducing drugs have the capacity to undergo transformation to reactive products by exposure to activated neutrophils (17) (18) (19) (20) (21) . There is a general correlation between susceptibility to neutrophil-mediated transformation and propensity to induce lupus (17) ; chemical analogs of each drug such as the non-lupusinducing analog of procainamide, N-acetylprocainamide, were resistant to metabolic transformation by this mechanism.
Metabolism of drugs by activated neutrophils provides a mechansim for generating highly reactive metabolites directly within lymphoid tissue, where autoimmunity presumably develops. Because (10, 12, 17, 26) . PAHA has also been reported to be slightly mitogenic for human lymphocytes (10) . Other biologic properties have been demonstrated for PAHA including enhancing reactive oxygen species production by murine macrophage (27) and human neutrophils (10) and generating PAHA-specific murine T cells in vivo (28 (32) . As summarized in Table 1,   Table 1 . Evidence for thymic function in the adult.
Structural Functional Mouse
Lymphocytic islands in the aged thymus Reconstitution of the Vp repertoire after bone exhibit a T-cell subset distribution similar marrow transplantation in irradiated old to the young thymus (33) mice (34) Production of mature T cells de novo from mice >1 year of age (35) Positive and negative selection were retained despite thymic involution (36) Human Lymphocytic islands in the aged thymus Naive T-cell subsets are generated de novo exhibit a T-cell subset distribution similar from transplanted bone marrow or peripheral to the young thymus (37) stem cells after myelosuppression (38) DNA excision circles characteristic of newly formed T cells are detected in the circulation only in nonthymectomized elderly people (39) .
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THE THYMUS IN A MOUSE MODEL OF DRUG-INDUCED LUPUS
there is a growing body of evidence in the mouse and human that the thymus functions in the adult to produce mature T cells. Therefore, the machinery for preserving T-cell tolerance by this central immune organ must be maintained throughout life, and interference with this process by drugs could result in autoimmunity.
Disuption ofCentral T-Cell Tolerance Causes Lupus-Like Autoimmunity
To determine whether disruption of central T-cell tolerance by lupus-inducing drugs could result in autoimmunity, PAHA was injected into the thymus of young adult (C57BL/6xDBA/2)F1 mice. Two intrathymic injections with the drug resulted in the rapid appearance of IgM anti-denatured DNA antibodies, followed by a delayed but sustained production of IgG antichromatin antibodies (Figure 1 ) (40) . Specificity, inhibition, and blocking studies demonstrated that the serology of PAHA-treated mice had a striking resemblance to that of patients with procainamide-induced lupus, suggesting that the immune system had undergone similar perturbations in both species (Figure 2 Presently there is no evidence that druginduced lupus in humans is initiated when central T-cell tolerance is disrupted by the action of reactive drug metabolites in the thymus. The most compelling argument that the thymus is the critical target of xenobiotic action is a) this organ is the only site in the mouse where PAHA presence initiates systemic autoimmunity and b) the specificity of PAHA-induced autoantibodies in the mouse is very similar to those in patients with drug-induced lupus. It is possible that Time after first PAHA injection (days) 
